{
    "id": "5e44c18648dab47f2600001f",
    "question": "Does gavestinel improve outcomes of stroke patients?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "Here is the step-by-step thinking and the final answer in JSON format: {\"step_by_step_thinking\": \"To answer this question, we need to analyze the relevant documents and look for information about gavestinel and its effects on stroke patients. Gavestinel is a drug that is not mentioned in the provided documents. However, we can infer that the question is asking whether gavestinel has any known effects on stroke patients based on the information provided about other drugs and treatments. Based on the documents, we can see that the effects of various drugs and treatments on stroke patients are discussed, including the use of aspirin, anticoagulants, and thrombolytics. However, gavestinel is not mentioned in the documents. Therefore, we cannot determine the answer to this question based on the provided information. However, based on general knowledge, gavestinel is a drug that is used to treat epilepsy and is not typically used to treat stroke. It is a nonbenzodiazepine anxiolytic drug that is used to treat anxiety disorders. Therefore, it is unlikely to improve outcomes for stroke patients. Based on this information, the most likely answer is B. no.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_29910",
            "title": "InternalMed_Harrison",
            "content": "Patient care in stroke units followed by rehabilitation services improves neurologic outcomes and reduces mortality. Use of clinical pathways and staff dedicated to the stroke patient can improve care. This includes use of standardized stroke order sets. Stroke teams that provide emergency 24-h evaluation of acute stroke patients for acute medical management and consideration of thrombolysis or endovascular treatments are essential components of primary and comprehensive stroke centers, respectively."
        },
        {
            "id": "Neurology_Adams_6381",
            "title": "Neurology_Adams",
            "content": "The relative advantages of placing the seriously ill acute stroke patient in a special stroke unit have been the subject of much study. The outcome in these patients in terms of morbidity and mortality is improved, although the differences have been small and difficult to document. However, this organizational plan has not been widely implemented and instead protocols for rapid evaluation of stroke and the emergence of a specialty of stroke neurology have proliferated. If nothing else, this is the result of a general recognition that stroke, like myocardial infarction, requires special expertise and focus. Protocols to prevent excessive hypertension after thrombolytic treatment are best instituted in units that have staffing patterns that create familiarity with these and other protocols. As already emphasized, the prevention of aspiration and pneumonia is paramount by identifying those patients at risk. The patients at risk also benefit from systematic application of protocols. Also"
        },
        {
            "id": "InternalMed_Harrison_29893",
            "title": "InternalMed_Harrison",
            "content": "The National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study showed a clear benefit for IV rtPA in selected patients with acute stroke. The NINDS study used IV rtPA (0.9 mg/kg to a 90-mg maximum; 10% as a bolus, then the remainder over 60 min) versus placebo in ischemic stroke within 3 h of onset. One-half of the patients were treated within 90 min. Symptomatic intra-cranial hemorrhage occurred in 6.4% of patients on rtPA and 0.6% 2562 on placebo. In the rTPA group, there was a significant 12% absolute increase in the number of patients with only minimal disability (32% on placebo and 44% on rtPA) and a nonsignificant 4% reduction in mortality (21% on placebo and 17% on rtPA). Thus, despite an increased incidence of symptomatic intracranial hemorrhage, treatment with IV rtPA within 3 h of the onset of ischemic stroke improved clinical outcome. Three subsequent trials of IV rtPA did not confirm this benefit, perhaps because of the dose of rtPA used, the timing"
        },
        {
            "id": "Neurology_Adams_6355",
            "title": "Neurology_Adams",
            "content": "The benchmark study organized by the National Institute of Neurological and Communicative Disorders and Stroke (see the NINCDS and Stroke rtPA Stroke Study Group in the references) provided evidence of benefit from intravenous tPA. Treatment within 3 h of the onset of symptoms led to a 30 percent increase in the number of patients who remained with little or no neurologic deficit when examined 3 months after the stroke; this benefit persisted when assessed 1 year later in the study by Kwiatkowski and associates. Two aspects are notable: the benefits extended to all types of ischemic strokes, including those caused by occlusion of small vessels (lacunes), and improvement was not apparent in the days immediately following treatment, only when patients were examined at 3 months."
        },
        {
            "id": "Surgery_Schwartz_14002",
            "title": "Surgery_Schwartz",
            "content": "patients with atrial fibrillation results in small stroke reduction but increased bleeding risk and substantial inconvenienceUncertainty or variability in values and preferencesYoung patients with lymphoma will invariably place a highervalue on the life prolonging effects of chemotherapy than on treatment toxicityOlder patients with lymphoma may not place a higher value on the life prolonging effects of chemotherapy than on treatment toxicityUncertainty about whether the intervention represents a wise use of resourcesThe low cost of aspirin as prophylaxis against stroke in patients with transient ischemic attacksThe high cost of clopidogrel and of combination dipyridamole and aspirin as prophylaxis against stroke in patients with transient ischaemic attacks1. An explicit description of development and funding pro-cesses that is publicly available.2. A transparent process that minimizes bias, distortion, and conflicts of interest.3. Developed by a multidisciplinary panel composed of:"
        },
        {
            "id": "InternalMed_Harrison_29895",
            "title": "InternalMed_Harrison",
            "content": "than in the 0to 3-h time window. In the rtPA group, 52.4% of patients achieved a good outcome at 90 days, compared to 45.2% of the placebo group (odds ratio [OR] 1.34, p = .04). The symptomatic intra-cranial hemorrhage rate was 2.4% in the rtPA group and 0.2% in the placebo group (p = .008). Based on these data, rtPA is approved in the 3to 4.5-h window in Europe and Canada, but is still only approved for 0\u20133 h in the United States and Canada. Use of IV tPA is now considered a central component of primary stroke centers (see below). It represents the first treatment proven to improve clinical outcomes in ischemic stroke and is cost-effective and cost-saving. Advanced neuroimaging techniques (see neuroimaging section below) may help to select patients beyond the 4.5-h window who will benefit from thrombolysis, but this is currently investigational. The time of stroke onset is defined as the time the patient\u2019s symptoms were witnessed to begin or the time the patient was last seen as"
        },
        {
            "id": "InternalMed_Harrison_29968",
            "title": "InternalMed_Harrison",
            "content": "there were no differences in the rates of second stroke (9% each) or degree of disability in patients with median follow-up of 2.4 years. Telmisartan also had no effect on these outcomes. This suggests that these anti-platelet regimens are similar and also raises questions about default prescription of agents to block the angiotensin pathway in all stroke patients. The principal side effect of dipyridamole is headache. The combination capsule of extended-release dipyridamole and aspirin is approved for prevention of stroke."
        },
        {
            "id": "InternalMed_Harrison_29894",
            "title": "InternalMed_Harrison",
            "content": "IV rtPA within 3 h of the onset of ischemic stroke improved clinical outcome. Three subsequent trials of IV rtPA did not confirm this benefit, perhaps because of the dose of rtPA used, the timing of its delivery, and small sample size. When data from all randomized IV rtPA trails were combined, however, efficacy was confirmed in the <3-h time window, and efficacy likely extended to 4.5 h and possibly to 6 h. Based on these combined results, the European Cooperative Acute Stroke Study (ECASS) III explored the safety and efficacy of rtPA in the 3to 4.5-h time window. Unlike the NINDS study, patients older than 80 years of age and diabetic patients with a previous stroke were excluded. In this 821-patient randomized study, efficacy was again confirmed, although the treatment effect was less robust than in the 0to 3-h time window. In the rtPA group, 52.4% of patients achieved a good outcome at 90 days, compared to 45.2% of the placebo group (odds ratio [OR] 1.34, p = .04). The symptomatic"
        },
        {
            "id": "Neurology_Adams_6393",
            "title": "Neurology_Adams",
            "content": "Aspirin does not appear to afford the same degree of protective benefit as does anticoagulation for primary risk stroke reduction in atrial fibrillation, and some studies suggest if there are no other risk factors for stroke, there may be slightly better risk reduction for stroke with aspirin than with no treatment. For patients under age 65 and without other risk factors for stroke, reflected usually by a low CHADS score, aspirin may be reasonable preventive measure. The appropriate dose of aspirin has not been established but former trials of very large doses, for example, 1 g/d, conferred risk of bleeding."
        },
        {
            "id": "Neurology_Adams_6369",
            "title": "Neurology_Adams",
            "content": "Swanson has reviewed several trials evaluating heparin (including the International Stroke Trial and the TOAST study) and suggested that there was no net benefit from heparin in acute stroke because of an excess of cerebral hemorrhages. However, in these series there was a low incidence, estimated as 2 percent, of recurrent stroke in the first weeks after a cerebral infarction in the untreated groups. An early recurrent stroke rate this low almost precludes demonstrating a benefit from the use of heparin or heparinoid drugs. The issue of administering heparin or low molecular weight heparin subcutaneously in cases of recent cardioembolic cerebral infarction, particularly as a \u201cbridge,\u201d while waiting for the effects of an oral anticoagulant to be established is addressed further on. Heparin is also used by some practitioners in stuttering small vessel lacunar stroke but the effects are uncertain."
        },
        {
            "id": "InternalMed_Harrison_20749",
            "title": "InternalMed_Harrison",
            "content": "(See also Chap. 446) Stroke is a common cause of neurologic critical illness. Hypertension must be managed carefully, since abrupt reductions in blood pressure may be associated with further brain ischemia and injury. Acute ischemic stroke treated with tissue plasminogen activator (tPA) has an improved neurologic outcome when treatment is given within 3 h of onset of symptoms. The mortality rate is not reduced when tPA is compared with placebo, despite the improved neurologic outcome. The risk of cerebral hemorrhage is significantly higher in patients given tPA. No benefit is seen when tPA therapy is given beyond 3 h after symptom onset. Heparin has not been convincingly shown to improve outcomes in patients with acute ischemic stroke. Decompressive cra-1735 niectomy is a surgical procedure that relieves increased intracranial pressure in the setting of space-occupying brain lesions or brain swelling from stroke; available evidence suggests that this procedure may improve survival"
        },
        {
            "id": "Neurology_Adams_6390",
            "title": "Neurology_Adams",
            "content": "Primary and Secondary Prevention of Ischemic Stroke In addition to reduction in the well-known risk factors for vascular disease, certain measures have been shown to reduce the risk of a subsequent stroke and to prevent a first stroke. Many of these approaches have required large randomized trials, sometimes in selected populations, in order to demonstrate significant differences compared to no treatment or to various comparators. For this reason, it is often uncertain how to apply these findings to the individual patient but they have found their way into guidelines. Anticoagulants for the Primary Prevention of Strokes (See Table 33-3)"
        },
        {
            "id": "InternalMed_Harrison_225",
            "title": "InternalMed_Harrison",
            "content": "choices; some will have events regardless of which treatment is selected; and those who avoided having an event through treatment cannot be individually identified. Blood pressure lowering, a readily observable surrogate endpoint, does not have a tightly coupled relationship with strokes prevented. Consequently, demonstrating therapeutic effectiveness cannot rely simply on observing the outcome of an individual patient but should instead be based on large groups of patients carefully studied and properly analyzed."
        },
        {
            "id": "InternalMed_Harrison_19603",
            "title": "InternalMed_Harrison",
            "content": "After a stroke, combination therapy with an ACEI and a diuretic, but not with an ARB, has been reported to reduce the rate of recurrent stroke. Some of these apparent differences may reflect differences in trial design and/or patient groups."
        },
        {
            "id": "InternalMed_Harrison_29905",
            "title": "InternalMed_Harrison",
            "content": "21,106 patients with ischemic stroke received 160 mg/d of aspirin or a placebo for up to 4 weeks. There were very small reductions in the aspirin group in early mortality (3.3 vs 3.9%), recurrent ischemic strokes (1.6 vs 2.1%), and dependency at discharge or death (30.5 vs 31.6%). These trials demonstrate that the use of aspirin in the treatment of AIS is safe and produces a small net benefit. For every 1000 acute strokes treated with aspirin, about 9 deaths or nonfatal stroke recurrences will be prevented in the first few weeks and ~13 fewer patients will be dead or dependent at 6 months."
        },
        {
            "id": "Neurology_Adams_6376",
            "title": "Neurology_Adams",
            "content": "with modified Rankin scale scores of 4, meaning they are dependent on others for their personal care. A controlled trial conducted in patients over age 60 has confirmed a beneficial effect of hemicraniectomy in preventing death from brain swelling after stroke. However, not surprisingly, the proportion of survivors with good functional outcomes in this older group was not as high as for younger patients."
        },
        {
            "id": "InternalMed_Harrison_29887",
            "title": "InternalMed_Harrison",
            "content": "After the clinical diagnosis of stroke is made, an orderly process of evaluation and treatment should follow (Fig. 446-1). The first goal is to prevent or reverse brain injury. Attend to the patient\u2019s airway, breathing, and circulation (ABCs), and treat hypoglycemia or hyperglycemia if identified. Perform an emergency noncontrast head CT scan to differentiate between ischemic stroke and hemorrhagic stroke; there are no reliable clinical findings that conclusively separate ischemia from hemorrhage, although a more depressed level of consciousness, higher initial blood pressure, or worsening of symptoms after onset favor hemorrhage, and a deficit that is maximal at onset, or remits, suggests ischemia. Treatments designed to reverse or lessen the amount of tissue infarction and improve clinical outcome fall within six categories: (1) medical support, (2) IV thrombolysis, (3) endovascular revascularization, (4) antithrombotic treatment, (5) neuroprotection, and (6) stroke centers and"
        },
        {
            "id": "Neurology_Adams_6407",
            "title": "Neurology_Adams",
            "content": "In trials comparing aspirin to anticoagulation for secondary stroke prevention in atrial fibrillation, anticoagulation has still been superior (see ACTIVE Writing Group). These studies notwithstanding, the therapeutic effectiveness of aspirin is still rather slight and the addition of clopidogrel to aspirin in patients who were not deemed suitable for warfarin reduces strokes over several years of observation but increases the risk of major bleeding so that the combination cannot be endorsed (ACTIVE Investigators). Moreover, in each of the trials, a significant number of subsequent ischemic strokes occurred even in patients while they were receiving aspirin."
        },
        {
            "id": "Neurology_Adams_6360",
            "title": "Neurology_Adams",
            "content": "Generally excluded from thrombolysis are those patients in whom the deficit is either very small (e.g., hand affected only, dysarthria alone, minor aphasia), rapidly improving, or more importantly, is so large as to implicate almost the entire territory of the middle cerebral artery. Many centers have expanded their practices beyond the confines of the initial NIH study, treating patients older than age 80 years and some with large strokes. Also ambiguous is the treatment with tPA of patients with acute stroke in whom the referable cerebral vessels are entirely patent. Often, the patency of the vessel is not known. Public health education should increase the numbers of stroke patients who seek early attention and thus raise the proportion who are eligible for tPA treatment."
        },
        {
            "id": "Neurology_Adams_6218",
            "title": "Neurology_Adams",
            "content": "but, interestingly, found that regions just adjacent to them are hyperperfused. These concepts find a parallel in attempts to demonstrate by imaging matching of perfusion and infarction (detected by diffusion-weighted images on MRI) in patterns with acute stroke as discussed in the section on treatment. Elevating the systemic blood pressure or improving the rheologic flow properties of blood in small vessels by hemodilution improves flow in the penumbra; however, attempts to use that techniques in clinical work has met with mixed success. Reperfusion of the penumbral area by removal of the occluding clot has, however, been successful in improving outcome after stroke."
        },
        {
            "id": "Anatomy_Gray_2783",
            "title": "Anatomy_Gray",
            "content": "The risk factors for stroke are those of cardiovascular disease, such as diabetes, hypertension, and smoking. In younger patients underlying clotting disorders, use of oral contraceptives, and illicit substance abuse (such as cocaine) are additional causes. The symptoms and signs of a stroke depend on the distribution of impaired brain perfusion. Common presentations include rapid-onset hemiparesis or hemisensory loss, visual field deficits, dysarthria, ataxia, and a decreased level of consciousness. Stroke is a neurological emergency. It is therefore important to establish the diagnosis as early as possible so that urgent and potentially life-saving treatment can be administered. Potent thrombolytic (blood-thinning) drugs can restore cerebral blood flow and improved patient outcome if administered within 3 to 4.5 hours of onset of the patient\u2019s symptoms."
        },
        {
            "id": "Neurology_Adams_6401",
            "title": "Neurology_Adams",
            "content": "Aspirin has proved to be the most consistently useful drug in the prevention of thrombotic and possibly, embolic strokes but its effects have been small in large trials both for primary prevention and for reducing the risk of a recurrent stroke. The acetyl moiety of aspirin combines with the platelet membrane and inhibits platelet cyclooxygenase, thus preventing the production of thromboxane A2, a vasoconstricting prostaglandin, and also prostacyclin, a vasodilating prostaglandin. One currently favored approach, based in part on the WARSS trial, is to simply administer aspirin in all cases of acute stroke. This approach is further endorsed by the WASID trial comparing aspirin (1,300 mg/d) to warfarin for treatment of intracranial arterial stenosis on the basis that warfarin was no better at preventing strokes while aspirin was associated with fewer gastrointestinal hemorrhages and a lower overall death rate. Confirmation of this approach was given by the IST and CAST trials that"
        },
        {
            "id": "Surgery_Schwartz_7735",
            "title": "Surgery_Schwartz",
            "content": "plus topi-ramate\u2013extended release at 1 year. The proportion of patients achieving clinically meaningful (at least 5%) weight loss ranges from 37% to 47% for lorcaserin, 35% to 73% for orlistat, and 67% to 70% for higher-dose phentermine plus topiramate\u2013extended release. All three of these medications produce greater improvements in cardiometabolic risk factors than placebo, Brunicardi_Ch27_p1167-p1218.indd 117223/02/19 2:20 PM 1173THE SURGICAL MANAGEMENT OF OBESITYCHAPTER 27but none has been shown to reduce cardiovascular morbid-ity or mortality. There is limited data for the long-term safety and efficacy of these medications, and some of these drugs may increase heart rate43 or attenuate expected blood pressure reductions.47 In addition, completed trials of hard cardiovascular disease outcomes (heart attack and stroke) in patients treated with these medications have yet to be published, except in the case of liraglutide.43 Figure 27-4 shows a comparison of weight loss outcomes"
        },
        {
            "id": "InternalMed_Harrison_29967",
            "title": "InternalMed_Harrison",
            "content": "Stroke Prevention Study (ESPS) II showed efficacy of both 50 mg/d of aspirin and extended-release dipyridamole in preventing stroke, and a significantly better risk reduction when the two agents were combined. The open-label ESPRIT (European/Australasian Stroke Prevention in Reversible Ischaemia Trial) trial confirmed the ESPS-II results. After 3.5 years of follow-up, 13% of patients on aspirin and dipyridamole and 16% on aspirin alone (hazard ratio 0.80, 95% confidence index [CI] 0.66\u2013 0.98) met the primary outcome of death from all vascular causes. In the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, the combination of extended-release dipyridamole and aspirin was compared directly with clopidogrel with and without the angiotensin receptor blocker telmisartan; there were no differences in the rates of second stroke (9% each) or degree of disability in patients with median follow-up of 2.4 years. Telmisartan also had no effect on these outcomes. This"
        },
        {
            "id": "Neurology_Adams_6366",
            "title": "Neurology_Adams",
            "content": "Several considerations weigh in any discussion of the institution and choice of antiplatelet or anticoagulant treatment (meant here to denote the agents that alter the clotting cascade) for stroke. First is the distinction between anticoagulation to prevent the progression of an acute stroke and the prophylactic use of anticoagulation for the prevention of future strokes. Second, the pivotal issue in prevention of further strokes is whether the stroke or TIA is atherothrombotic or cardioembolic. As discussed further on, several studies point conclusively to a role for anticoagulation in stroke due to certain cardioembolic sources, particularly atrial fibrillation, while the indications in acute stroke are less certain."
        },
        {
            "id": "Neurology_Adams_3926",
            "title": "Neurology_Adams",
            "content": "Whether contemporary methods of speech therapy accomplish more than can be accounted for by spontaneous recovery is still uncertain. Most aphasic disorders are caused by vascular disease and trauma, and they are nearly always accompanied by some degree of spontaneous improvement in the days, weeks, and months that follow the stroke or accident. A Veterans Administration Cooperative Study (Wertz et al) has suggested that intensive therapy by a speech pathologist does hasten improvement. Also, Howard and colleagues have shown increased efficacy of word retrieval in a group of chronic stable aphasics treated by two different techniques. More studies of this type, which control for the effects of time, of the patient\u2019s motivation and the interest of family and therapist, are needed. In an interesting personal experiment by Wender, a classicist who had become aphasic, practice of Greek vocabulary and grammar led to recovery in that language, but there was little recovery of her facility"
        },
        {
            "id": "Neurology_Adams_6356",
            "title": "Neurology_Adams",
            "content": "We make a comment here about the historically important, seminal NIH study, in which tPA was administered in a dose of 0.9 mg/kg, 10 percent of which was given as an initial bolus, followed by an infusion of the remainder over 1 h. A dose of 90 mg was not exceeded, this being lower than the dose used for myocardial infarction. The relative improvement in neurologic state came at the expense of a 6 percent risk of symptomatic cerebral hemorrhage and 4 percent of insignificant hemorrhages seen on imaging, that is, a lower rate than in most previous studies but twice the expected rate without thrombolysis (some of the hemorrhages were into the area of infarction and did not cause symptomatic worsening). Patients were excluded from the study if they had massive infarctions (encompassing more than two-thirds of the territory of the middle cerebral artery), had high scores on a clinical stroke scale that was devised for the National Institutes of Health (NIH) study (available at:"
        },
        {
            "id": "Neurology_Adams_6582",
            "title": "Neurology_Adams",
            "content": "In a randomized trial of rapid reduction in blood pressure in patients with acute cerebral hemorrhage, Anderson and colleagues (2013) found that targeting a level of systolic blood pressure below 140 mm Hg within an hour resulted in similar overall clinical outcomes and mortality to guideline-recommended treatment that targets a systolic blood pressure of less than 180 mm Hg. More rapidly acting and titratable agents such as nitroprusside may be used in extreme situations, recognizing that they may further raise intracranial pressure."
        },
        {
            "id": "Pharmacology_Katzung_1208",
            "title": "Pharmacology_Katzung",
            "content": "be valuable in treating silent or ambulatory ischemia. Because this condition causes no pain, it is usually detected by the appearance of typical electrocardiographic signs of ischemia. The total amount of \u201cischemic time\u201d per day is reduced by long-term therapy with a \u03b2 blocker. Beta-blocking agents decrease mortality of patients with heart failure or recent myocardial infarction and improve survival and prevent stroke in patients with hypertension. Randomized trials in patients with stable angina have shown better outcome and symptomatic improvement with \u03b2 blockers compared with calcium channel blockers."
        },
        {
            "id": "Neurology_Adams_6357",
            "title": "Neurology_Adams",
            "content": "more than two-thirds of the territory of the middle cerebral artery), had high scores on a clinical stroke scale that was devised for the National Institutes of Health (NIH) study (available at: http://www.ninds .nih.gov/doctors/NIH_Stroke_Scale.pdf and from other sources) had uncontrolled hypertension, were more than 80 years of age, or had recently received anticoagulants (except aspirin). Further analysis of the NINCDS trial revealed that patients who were treated earliest within the 3-h time frame had more benefit than those treated later; indeed, the administration of tPA in the time between 2.5 and 3 h after the stroke was of less value. One trial has suggested that a lower dose of tPA (0.6 mg/kg) is non-inferior to the standard dose in a population of predominantly Asian patients (Anderson et al 2016)."
        },
        {
            "id": "Neurology_Adams_6349",
            "title": "Neurology_Adams",
            "content": "some insight has been gained by the study of a cohort of patients with mild stroke or what have been considered to be \u201chigh-risk\u201d TIAs in the modern era by Amarenco and colleagues (2016 and 2018). They estimated recurrence rates of approximately 4 percent at 90 days, 5 percent at a year and another 6 percent between the end of the first year and the fifth year. The treatment of stroke may be divided into three broad parts: management in the acute phase by measures to restore the circulation and arrest the pathologic process, physical therapy and rehabilitation, and measures to prevent further strokes and progression of vascular disease."
        },
        {
            "id": "Neurology_Adams_6440",
            "title": "Neurology_Adams",
            "content": "These comments reflect the guidelines for asymptomatic carotid stenosis set forth by the American Heart Association in 2011 but there must be a careful evaluation of the circumstances in each patient, particularly the medical risk of endarterectomy, and a recognition that residual lumen diameters and percent stenoses are measured in different ways by varying techniques, both in the above-described studies and in clinical practice. Course and Prognosis of Ischemic Stroke"
        }
    ],
    "scores": [
        0.03634997613315342,
        0.03626616929437778,
        0.031263783810512785,
        0.029164029071907186,
        0.02484126303144708,
        0.024255894858909936,
        0.02403871618954343,
        0.02373647010114154,
        0.023596698135126645,
        0.02347977331162534,
        0.022435278425739558,
        0.02201737656283111,
        0.021728943684234295,
        0.021283491213344524,
        0.021217775934757065,
        0.02060785606246423,
        0.020474939753473163,
        0.019906607860810853,
        0.019823947813976048,
        0.018750547621133797,
        0.017879948914431672,
        0.017507645259938837,
        0.017284495439835245,
        0.017022792022792024,
        0.016698735568993952,
        0.01652780600149021,
        0.016335978835978836,
        0.015919959728165116,
        0.015893630179344465,
        0.015791945520723258,
        0.015503425850656137,
        0.01534090909090909
    ]
}